Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination
- PMID: 8807212
- PMCID: PMC170366
- DOI: 10.1128/cdli.3.4.451-455.1996
Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination
Abstract
The purpose of the present study was to explore the possibility of detecting antibodies to Shigella sonnei lipopolysaccharide (LPS) in urine after infection or vaccination. Urinary immunoglobulin A (IgA) and IgG antibodies and specific IgA secretory protein against S. sonnei LPS were measured by enzyme-linked immunosorbent assay (ELISA), after adjustment for urine concentration. A significant antibody level was defined as one above a cutoff value calculated from the geometric mean + 2 standard deviations of urinary anti-S. sonnei LPS levels in 43 healthy hepatitis B vaccinees (controls). Of 11 culture-proven cases of S. sonnei shigellosis, at convalescence 9 (82%) had significantly elevated levels of urinary antibodies to the homologous LPS. The S. sonnei conjugate vaccine, composed of S. sonnei O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa, elicited a significant urine IgA or IgG anti-LPS response in 60% (6 of 10), 56% (9 of 16) 43% (16 of 37), and 14% (3 of 21) of the volunteers at 2 weeks, 6 weeks, 6 months, and 12 months after vaccination, respectively. The specificity of the urine antibody response to S. sonnei LPS was documented by the total lack of response in subjects who received parenteral Shigella flexneri 2a-recombinant exoprotein A conjugate (69 urine samples) or meningoccal tetravalent control vaccines (4 urine samples). All the volunteers who lacked a significant response to S. sonnei LPS in serum also lacked such response in urine samples. Seventy-four percent of the volunteers with a significant IgA or IgG anti-LPS response in serum at convalescence or 14 days after vaccination showed a similar response in urine. The ratio of the titer of secretory protein bound to IgA anti-S. sonnei LPS in urine to that in serum was 303 times higher than the ratio of anti-S. sonnei LPS total IgA titer in urine to that in serum, indicating that the urine IgA is of secretory origin. These findings suggest the possible use of urinary Shigella LPS antibodies as markers of systemic and secretory immune responses after natural infection or vaccination. At this stage, because of its limited sensitivity, the detection by ELISA of Shigella LPS antibodies in urine cannot replace the same assay in serum as a definitive test in an individual with a negative result.
Similar articles
-
Detoxified O-Specific Polysaccharide (O-SP)-Protein Conjugates: Emerging Approach in the Shigella Vaccine Development Scene.Vaccines (Basel). 2022 Apr 24;10(5):675. doi: 10.3390/vaccines10050675. Vaccines (Basel). 2022. PMID: 35632431 Free PMC article. Review.
-
Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.Vaccine. 1999 Aug 6;17(23-24):3109-15. doi: 10.1016/s0264-410x(99)00136-x. Vaccine. 1999. PMID: 10462247 Clinical Trial.
-
Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study.PLoS One. 2021 May 27;16(5):e0252222. doi: 10.1371/journal.pone.0252222. eCollection 2021. PLoS One. 2021. PMID: 34043697 Free PMC article.
-
Shigella lipopolysaccharide antibodies in pediatric populations.Pediatr Infect Dis J. 1995 Oct;14(10):859-65. doi: 10.1097/00006454-199510000-00008. Pediatr Infect Dis J. 1995. PMID: 8584312
-
Shigellosis in Vietnam: seroepidemiologic studies with use of lipopolysaccharide antigens in enzyme immunoassays.Rev Infect Dis. 1991 Mar-Apr;13 Suppl 4:S231-7. doi: 10.1093/clinids/13.supplement_4.s231. Rev Infect Dis. 1991. PMID: 2047643 Review.
Cited by
-
Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human.Hum Vaccin Immunother. 2019;15(6):1338-1356. doi: 10.1080/21645515.2019.1606972. Hum Vaccin Immunother. 2019. PMID: 31158047 Free PMC article. Review.
-
Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin A responses in blood.Infect Immun. 1998 Jul;66(7):3311-6. doi: 10.1128/IAI.66.7.3311-3316.1998. Infect Immun. 1998. PMID: 9632600 Free PMC article.
-
Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.Infect Immun. 2001 Jul;69(7):4545-53. doi: 10.1128/IAI.69.7.4545-4553.2001. Infect Immun. 2001. PMID: 11401998 Free PMC article. Clinical Trial.
-
Detoxified O-Specific Polysaccharide (O-SP)-Protein Conjugates: Emerging Approach in the Shigella Vaccine Development Scene.Vaccines (Basel). 2022 Apr 24;10(5):675. doi: 10.3390/vaccines10050675. Vaccines (Basel). 2022. PMID: 35632431 Free PMC article. Review.
-
Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.Nat Rev Microbiol. 2007 Jul;5(7):540-53. doi: 10.1038/nrmicro1662. Nat Rev Microbiol. 2007. PMID: 17558427 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous